AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on the stock and has a p14,500.00 price target.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Sachin Jain’s rating is based on AstraZeneca’s strong growth prospects and an attractive valuation. The company’s valuation, approximately 14 times the estimated 2026 Price-to-Earnings ratio, is considered appealing, particularly with the potential for re-rating to an 18 times P/E ratio based on projected sales growth. AstraZeneca’s mid-term guidance suggests a high-single-digit sales compound annual growth rate, which supports the optimistic outlook.
Additionally, over the next 18 months, AstraZeneca is expected to deliver significant clinical trial results that could transform its business landscape. These include several key Phase III trials with a potential sales impact of around $30 billion. Among these, the Dato 1L NSCLC (AVANZAR) and Camizestrant SERENA-6 in ESR1m BC are highlighted as pivotal, alongside promising developments in hypertension, ATTR-CM, and HER2+ breast cancer treatments. These factors, coupled with two additional Phase III blockbuster trials for rare disease assets, underpin the Buy rating and reflect confidence in the company’s future performance.
In another report released today, Morgan Stanley also initiated coverage with a Buy rating on the stock with a p14,500.00 price target.